(Press-News.org) HOUSTON - A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology.
Eighteen newly diagnosed patients who were vaccinated after undergoing standard treatment - surgery followed by radiation and chemotherapy - had median overall survival of 26 months compared with 15 months for 17 patients in a control group who received standard treatment. Median survival for newly diagnosed patients with glioblastoma multiforme is 14.6 months.
Vaccinated patients also experienced a longer period before their disease progressed, 14.2 months, compared with 6.3 months for the control group. Side effects were limited mainly to irritation at the injection site.
"This promising targeted therapy blocks a key molecular signal that drives the malignant features of these tumors," said Amy Heimberger, M.D., associate professor in MD Anderson's Department of Neurosurgery and co-lead author of the paper. "If a patient's tumor expresses the target of this vaccine, she usually has only a 5 percent chance to live for two years."
All patients in the trial had the target variation, called epidermal growth factor receptor variant III (EGFRvIII), which occurs in about a third of glioblastomas and also is found in breast, lung and head and neck cancers. The flawed gene produces a protein that aids tumor development, migration and resistance to chemotherapy and radiation. It is not found in normal tissue.
Out of 11 tumor recurrences analyzed from vaccinated patients, the EGFRvIII cells were completely gone in nine, indicating that the vaccine had done its job eliminating the most aggressive cells, said co-lead author John Sampson, M.D., Ph.D., professor of Neurosurgery at Duke.
Other findings hint at the vaccine's likely effectiveness against EGFRvIII. Of six patients who had an immune response to the vaccine as indicated by blood tests, overall survival was 47.7 months compared with 22.8 months for those lacking a response. Median survival had not been reached after 50 months among three patients who had a T cell response to the vaccine.
However, the limited size of the sample calls for cautious interpretation of these results, Heimberger said. The next step for the vaccine, known as CDX-110, is a large phase III clinical trial, Heimberger said, which is in the planning stage.
The EGFRvIII variant was co-discovered by Bert Vogelstein, M.D., and Albert Wong, M.D., at Johns Hopkins University and Darrell Bigner, M.D., Ph.D., director of the brain tumor center at Duke and corresponding author of the JCO paper.
Glioblastomas have other molecular drivers, so tumors come back, which the authors say points to a need to develop vaccines that address more than one target.
Heimberger sees the addition of vaccines to glioblastoma treatment as one more way to convert the deadly tumors more of a chronic disease. Developments in recent years, including approval of the chemotherapy drug temozolomide, have extended expected survival from around seven months to 14.
INFORMATION:
Funding for the work came from the National Institutes of Health, the American Brain Tumor Association, Accelerate Brain Cancer Cure, the Brain Tumor Society, the Commonwealth Cancer Foundation, the Adam Singer Foundation, the Dr. Marnie Rose Foundation and Golfers Against Cancer.
Co-authors are Kenneth Aldape, Raymond Sawaya, Mark Gilbert, and Weiming Shi from MD Anderson; and Gary Archer, Allan Friedman, Henry Friedman, James Herndon II, Robert Schmittling, Roger McLendon, Duane Mitchell, David Reardon, and James Vredenburgh, from Duke.
Bigner, Heimberger and Sampson, along with Duke University and MD Anderson report potential conflicts of interest from consulting agreements, stock options and potential further licensing fees. The institutions have plans in place to manage them.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For seven of the past nine years, including 2010, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.
Vaccine extends glioblastoma patients' survival in phase II trial
2010-10-07
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Microfluidic devices advance 3-D tissue engineering at Stevens
2010-10-07
A research team, co-headed by Dr. Woo Lee and Dr. Hongjun Wang of Stevens Institute of Technology, has published a paper describing a new method that generates three-dimensional (3D) tissue models for studying bacterial infection of orthopedic implants. Dr. Joung-Hyun Lee of Stevens, and Dr. Jeffrey Kaplan of the New Jersey Dental School, are co-authors of the research. Their paper, appearing in the journal Tissue Engineering, demonstrates a physiologically relevant approach for studying infection prevention strategies and emulating antibiotic delivery using 3D bone tissues ...
UW-built device reveals invisible world teeming with microscopic algae
2010-10-07
It just got easier to pinpoint biological hot spots in the world's oceans where some inhabitants are smaller than, well, a pinpoint.
Microscopic algae are called phytoplankton and range from one to hundreds of microns in size – the smallest being 1/100th the size of a human hair. But as tiny as they may be, communities of the phytoplankton south of Vancouver Island, British Columbia, are big players when it comes to carbon: They take up 50 percent of the carbon dioxide going from the atmosphere into the oceans there.
"We thought that had to be a mistake at first," ...
Research suggests volcanoes nixed Neanderthals
2010-10-07
New research suggests that climate change following massive volcanic eruptions drove Neanderthals to extinction and cleared the way for modern humans to thrive in Europe and Asia.
The research, led by Liubov Vitaliena Golovanova and Vladimir Borisovich Doronichev of the ANO Laboratory of Prehistory in St. Petersburg, Russia, is reported in the October issue of Current Anthropology.
"[W]e offer the hypothesis that the Neanderthal demise occurred abruptly (on a geological time-scale) … after the most powerful volcanic activity in western Eurasia during the period of ...
Volcano fuels massive phytoplankton bloom
2010-10-07
Advocates for seeding regions of the ocean with iron to combat global warming should be interested in a new study published today in Geophysical Research Letters. A Canada-US team led by University of Victoria oceanographer Dr. Roberta Hamme describes how the 2008 eruption of the Kasatochi volcano in the Aleutian Islands spewed iron-laden ash over a large swath of the North Pacific. The result, says Hamme, was an "ocean productivity event of unprecedented magnitude"—the largest phytoplankton bloom detected in the region since ocean surface measurements by satellite began ...
Planet Neptune not guilty of harassment
2010-10-07
New research by a University of Victoria PhD student is challenging popular theory about how part of our solar system formed. At today's meeting of the prestigious Division of Planetary Sciences in Pasadena, California, Alex Parker is presenting evidence that, contrary to popular belief, the planet Neptune can't have knocked a collection of planetoids known as the Cold Classical Kuiper Belt to its current location at the edge of the solar system.
Parker and his thesis supervisor Dr. J.J. Kavelaars (Herzberg Institute of Astrophysics) studied binaries—systems of two objects ...
Number of synapses shown to vary between night and day in Stanford study of zebrafish
2010-10-07
STANFORD, Calif. — With the help of tiny, see-through fish, Stanford University School of Medicine researchers are homing in on what happens in the brain while you sleep. In a new study, they show how the circadian clock and sleep affect the scope of neuron-to-neuron connections in a particular region of the brain, and they identified a gene that appears to regulate the number of these connections, called synapses.
"This is the first time differences in the number of synapses between day and night and between wake and sleep have been shown in a living animal," said Lior ...
Competing motivational brain responses predict costly helping
2010-10-07
A new study reveals that brain signals elicited by the sight of someone suffering pain differ as a function of whether we identify positively or negatively with that person and that these differential brain signals predict a later decision to help or withdraw from helping. The research, published by Cell Press in the October 7th issue of the journal Neuron, provides fascinating insight into the neural mechanisms involved in decisions that benefit others, known as prosocial behavior, and how they are modulated by perceived group membership.
Dr. Tania Singer from the University ...
Immune system linked with accumulation of toxic tau protein
2010-10-07
Cells that help to protect the central nervous system may also contribute to pathological changes in the brain. New research, published by Cell Press in the October 7th issue of the journal Neuron, provides mechanistic insight into a link between the immune system and neurodegenerative disorders like Alzheimer's disease that are associated with abnormal accumulation of tau protein.
Tau is a protein found inside of neurons that acts almost like a skeleton, providing a supportive framework for the cell. However, abnormal tau sometimes clumps into filamentous deposits that ...
In Parkinson's disease, brain cells abandon mitochondria
2010-10-07
In a study that sheds new light on the causes of Parkinson's disease, researchers report that brain cells in Parkinson's patients abandon their energy-producing machinery, the mitochondria. A shutdown in fuel can have devastating effects on brain cells, which consume roughly 20 percent of the body's energy despite making up only 2 percent of body weight.
The findings indicate that boosting the mitochondria with FDA approved drugs early on may prevent or delay the onset of Parkinson's. The study will be published in the one-year anniversary issue of the journal Science ...
GUMC researchers find the blind use visual brain area to improve other senses
2010-10-07
Washington, DC – People who have been blind from birth make use of the visual parts of their brain to refine their sensation of sound and touch, according to an international team of researchers led by neuroscientists at Georgetown University Medical Center (GUMC).
Published today in the journal Neuron, the scientists say this finding helps explain why the blind have such advanced perception of these senses – abilities that far exceed people who can see, they say.
Using functional magnetic resonance imaging (fMRI), the researchers found that the blind use specialized ...